NS Pharma, Inc.
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$3.1M
Doctors Paid
601
Transactions
2,084
2024 Total
$753,101
Payment Breakdown by Category
Research$2.7M (86.2%)
Consulting$194,443 (6.3%)
Food & Beverage$47,359 (1.5%)
Travel$42,308 (1.4%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $2.7M | 617 | 86.2% |
| Consulting Fee | $194,443 | 56 | 6.3% |
| Honoraria | $124,408 | 137 | 4.0% |
| Food and Beverage | $47,359 | 1,188 | 1.5% |
| Travel and Lodging | $42,308 | 76 | 1.4% |
| Grant | $19,000 | 10 | 0.6% |
Payments by Type
Research
$2.7M
617 transactions
General
$427,517
1,467 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| NS-065/NCNP-01-202 - A Phase II, Open-Label, Extension Study to Assess the Safety and Efficacy of NS-065/NCNP-01 in Boys with Duchenne Muscular Dystrophy (DMD) | $903,953 | 0 | 86 |
| A Phase 2 Open-label Study to Assess the Safety, Tolerability, and Efficacy of Viltolarsen in Ambulant and Non-Ambulant Boys with Duchenne Muscular Dystrophy (DMD) Compared to Natural History Controls | $344,980 | 0 | 18 |
| Trial of Efficacy and Safety of NS-229 Versus Placebo in Patients With Eosinophilic Granulomatosis With Polyangiitis | $262,154 | 2 | 19 |
| NS-089/NCNP-02-201 in Boys With Duchenne Muscular Dystrophy (DMD) | $222,038 | 0 | 25 |
| Long-term Use of Viltolarsen in Boys With Duchenne Muscular Dystrophy in Clinical Practice (VILT-502) | $185,869 | 0 | 103 |
| A Phase 2 Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of NS-089/NCNP-02 in Boys With Duchenne Muscular Dystrophy (DMD) | $140,551 | 0 | 21 |
| A Phase 3 Randomized, Double-blind, Placebo-controlled, Multi-center Study to Assess the Efficacy and Safety of Viltolarsen in Ambulant Boys With Duchenne Muscular Dystrophy (DMD) | $121,204 | 0 | 29 |
| A Phase 2 Open-label Study to Assess the Safety, Tolerability, and Efficacy of Viltolarsen in Ambulant and Non-Ambulant Boys With Duchenne Muscular Dystrophy (DMD) Compared to Natural History Controls | $103,048 | 0 | 14 |
| NS-050/NCNP-03 in Boys With DMD (Meteor50) | $96,172 | 0 | 7 |
| A Phase 1/2, Open-label, Dose-Escalation Multi-center Study to Assess the Safety, Tolerability, PK and PD of Orally AdministeredNS-018in Patients With Primary Myelofibrosis (MF), Post-polycythemia Vera MF, or Post-essential Thrombocythemia MF | $62,467 | 0 | 70 |
| A Phase 3, Multi-center, Open-label Extension Study to Assess the Safety and Efficacy of Viltolarsen in Ambulant Boys With Duchenne Muscular Dystrophy (DMD) | $55,396 | 0 | 8 |
| Study to Assess Efficacy and Safety of NS-018 Compared to BAT in Patients With Myelofibrosis | $47,721 | 0 | 96 |
| Phase 4, open-label, single-arm clinical trial assessing the long-term safety and efficacy of Viltepso (viltolarsen) in boys with Duchenne muscular dystrophy (DMD) who completed a prior trial | $32,464 | 0 | 28 |
| Randomized, Controlled Clinical Trial (Phase 2B) Of Ns-018 Versus Best Available Therapy In Subjects With Primary Or Secondary Myelofibrosis With Severe Thrombocytopenia | $32,204 | 0 | 80 |
| Viltolarsen (NS-065/NCNP-01), Ilginatinib(NS-018), Exon 44 skipping DMD therapeutic(NS-089/NCNP-02) | $24,253 | 0 | 2 |
| A Phase 1/2, Open-label, Dose-escalation, Multi-center Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Orally Administered NS-018 in Patients with Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis | $13,822 | 0 | 7 |
| A Phase II, Open-Label, Extension Study to Assess the Safety and Efficacy of NS-065/NCNP-01 in Boys With Duchenne Muscular Dystrophy (DMD) | $10,064 | 0 | 2 |
| A Phase 3 Randomized, Double-blind, Placebo-controlled, Multi-center Study to Assess the Efficacy and Safety of Viltolarsen in Ambulant Boys with Duchenne Muscular Dystrophy (DMD) | $5,000 | 0 | 2 |
Payments by Medical Specialty
Top Paid Doctors
| Doctor | Specialty | Location | Total | 2024 |
|---|---|---|---|---|
| Peter Merkel, Md, Mph, MD, MPH | Rheumatology | Radnor, PA | $65,229 | $0 |
| Dr. Paula Clemens, Md, MD | Specialist | Pittsburgh, PA | $61,807 | $0 |
| Kan Hor, M.d, M.D | Pediatric Critical Care Medicine | Columbus, OH | $58,100 | $0 |
| John Jefferies, M.d, M.D | Pediatric Cardiology | Memphis, TN | $25,304 | $0 |
| Srdan Verstovsek, M.d., Phd, M.D., PHD | Medical Oncology | Houston, TX | $22,400 | $0 |
| Dr. Mathula Thangarajh, Md, Phd, MD, PHD | Neurology with Special Qualifications in Child Neurology | Richmond, VA | $21,468 | $0 |
| Dr. Ronald Farkas, M.d, M.D | Specialist | Clarksville, MD | $10,430 | $0 |
| Dr. Maurice Sholas, Md, Phd, MD, PHD | Cardiovascular Disease | Atlanta, GA | $10,123 | $0 |
| Dr. Michelle Figueroa, M.d, M.D | Pediatrics | Detroit, MI | $9,482 | $0 |
| Stanley Nelson, Md, MD | Pediatrics | Los Angeles, CA | $7,955 | $0 |
| Dr. John Bissler, Md, MD | Pediatric Nephrology | Memphis, TN | $7,700 | $0 |
| Gennady Bratslavsky, M.d, M.D | Urology | Syracuse, NY | $7,300 | $0 |
| Andreas Barth, M.d, M.D | Clinical Cardiac Electrophysiology | Baltimore, MD | $7,100 | $0 |
| Kevin Winthrop, Md, MD | Infectious Disease | Portland, OR | $4,970 | $0 |
| Dr. Katherine Mathews, Md, MD | Neuromuscular Medicine | Iowa City, IA | $4,200 | $0 |
| Erika Finanger, M.d, M.D | Neurology with Special Qualifications in Child Neurology | Portland, OR | $2,848 | $0 |
| Eric Ruderman, Md, MD | Rheumatology | Chicago, IL | $2,813 | $0 |
| Dr. Aravindhan Veerapandiyan, Md, MD | Neurology with Special Qualifications in Child Neurology | Little Rock, AR | $2,512 | $0 |
| Dr. Chamindra Laverty, M.d, M.D | Neuromuscular Medicine | San Diego, CA | $2,439 | $0 |
| Ana Tesi Rocha, Md, MD | Neurology with Special Qualifications in Child Neurology | Palo Alto, CA | $2,282 | $0 |
| Ioana Preston, Md, MD | Critical Care Medicine | Burlington, MA | $2,246 | $0 |
| Dr. Diana Castro, Md, MD | Student in an Organized Health Care Education/Training Program | Denton, TX | $1,904 | $0 |
| Edward Smith, Md, MD | Pediatrics | Durham, NC | $1,876 | $0 |
| Priya Verghese, Md, MD | Pediatric Nephrology | Chicago, IL | $1,860 | $0 |
| John Brandsema, Md, MD | Neurology with Special Qualifications in Child Neurology | Philadelphia, PA | $1,753 | $0 |
Ad
Top Products
- VILTEPSO $2.1M
- Viltepso $36,332
Associated Products (3)
- VILTEPSO $2.1M
- Viltepso $36,332
- Viltolarsen (NS-065/NCNP-01) $34,581
Payment Categories
- Food & Beverage $47,359
- Consulting $194,443
- Travel & Lodging $42,308
- Research $2.7M
About NS Pharma, Inc.
NS Pharma, Inc. has made $3.1M in payments to 601 healthcare providers, recorded across 2,084 transactions in the CMS Open Payments database. In 2024, the company paid $753,101. The top product by payment volume is VILTEPSO ($2.1M).
Payments were distributed across 60 medical specialties. The top specialty by payment amount is Specialist ($74,609 to 11 doctors).
Payment categories include: Food & Beverage ($47,359), Consulting ($194,443), Research ($2.7M), Travel & Lodging ($42,308).
NS Pharma, Inc. is associated with 3 products in the CMS Open Payments database.